Neurofilaments and tau proteins in cerebrospinal fluid and serum in dementias and neuroinflammation.

AIMS The aim of this study was to evaluate the diagnostic potential of cerebrospinal fluid (CSF) and serum levels of neurocytoskeletal proteins and their ratios for the diagnosis of dementias and to assess the differences in neurocytoskeletal proteins between neurodegeneration and neuroinflammation. METHODS CSF and serum levels of neurofilament light subunits (NFL) and neurofilament heavy subunits (NFH) as well as CSF levels of total tau (t-tau) and phosphorylated tau (p-tau) proteins were determined using ELISA in 20 Alzheimer's disease patients (AD group), 13 patients with other dementias (OD group), 17 patients with inflammatory aseptic neuro-infections (IP), and 20 aged-matched cognitively normal elderly persons (NC group). RESULTS The ratio CSF p-tau/t-tau was significantly higher in the NC group than that in the AD or OD groups (P<0.0005 for each group). The CSF NFH/p-tau and CSF NFL/p-tau ratios were significantly lower in AD patients than OD patients (P≤0.003). Serum and CSF NFL and CSF NFH levels were significantly higher in OD patients than AD patients (P≤0.03). The lowest values of the CSF NFL/NFH ratio were found in the IP group and they significantly differed from those in normal controls (P<0.0001) and any dementia group (IP vs. AD P<0.0001; IP vs. OD P=0.03). CONCLUSION CSF tau proteins and their index differentiated between AD or OD patients and cognitively normal subjects, while CSF levels of neurofilaments expressed as their index seem to contribute to the discrimination between patients with neuroinflammation and normal controls or AD patients.

[1]  K. Blennow,et al.  Subcortical Vascular Dementia Biomarker Pattern in Mild Cognitive Impairment , 2009, Dementia and Geriatric Cognitive Disorders.

[2]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[3]  Henrik Zetterberg,et al.  Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa , 2016, Clinical chemistry and laboratory medicine.

[4]  Xiongwei Zhu,et al.  Neurofilamentopathy in Neurodegenerative Diseases , 2011, The open neurology journal.

[5]  W. M. van der Flier,et al.  Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes , 2015, Alzheimer's & dementia.

[6]  M N Rossor,et al.  A Systematic Review and Meta-Analysis of CSF Neurofilament Protein Levels as Biomarkers in Dementia , 2007, Neurodegenerative Diseases.

[7]  H. Zetterberg Cerebrospinal fluid biomarkers for Alzheimer's disease: current limitations and recent developments , 2015, Current opinion in psychiatry.

[8]  B. Mollenhauer,et al.  Quantification of CSF biomarkers using an electrochemiluminescence-based detection system in the differential diagnosis of AD and sCJD , 2015, Journal of Neurology.

[9]  P. Kaňovský,et al.  Cerebrospinal fluid levels of chromogranin A and phosphorylated neurofilament heavy chain are elevated in amyotrophic lateral sclerosis , 2017, Acta neurologica Scandinavica.

[10]  N. Mattsson CSF biomarkers in neurodegenerative diseases , 2011, Clinical chemistry and laboratory medicine.

[11]  J. Fleming,et al.  A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking , 2009, Neurology.

[12]  John R Hodges,et al.  The Addenbrooke's Cognitive Examination Revised (ACE‐R): a brief cognitive test battery for dementia screening , 2006, International journal of geriatric psychiatry.

[13]  James C. Vickers,et al.  Defining the Earliest Pathological Changes of Alzheimer’s Disease , 2016, Current Alzheimer research.

[14]  J. Morrison,et al.  Alterations in neurofilament protein immunoreactivity in human hippocampal neurons related to normal aging and Alzheimer's disease , 1994, Neuroscience.

[15]  P. Scheltens,et al.  Serial CSF sampling in Alzheimer's disease: specific versus non-specific markers , 2012, Neurobiology of Aging.

[16]  L. Kurlowicz,et al.  The Mini Mental State Examination (MMSE). , 1999, Director.

[17]  Alzheimer's Disease Neuroimaging Initiative Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease , 2017 .

[18]  Henrik Zetterberg,et al.  Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease , 2017, JAMA neurology.

[19]  R. Lindberg,et al.  Neurofilament heavy chain and heat shock protein 70 as markers of seizure‐related brain injury , 2012, Epilepsia.

[20]  P. Adlard,et al.  The cause of neuronal degeneration in Alzheimer's disease , 2000, Progress in Neurobiology.

[21]  D. Schöttle,et al.  The Neurofilament Heavy Chain (NfHSMI35) in the Cerebrospinal Fluid Diagnosis of Alzheimer’s Disease , 2006, Dementia and Geriatric Cognitive Disorders.

[22]  M. Strong,et al.  Post-transcriptional control of neurofilaments: New roles in development, regeneration and neurodegenerative disease , 2010, Trends in Neurosciences.

[23]  K. Blennow,et al.  Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: results from the Swedish Mortality Registry. , 2014, JAMA neurology.

[24]  P. Scheltens,et al.  Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[25]  K. Blennow,et al.  Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD , 2000, Neurology.

[26]  I. Dujmovic Cerebrospinal Fluid and Blood Biomarkers of Neuroaxonal Damage in Multiple Sclerosis , 2011, Multiple sclerosis international.

[27]  B. Hemmer,et al.  EFNS guidelines on disease‐specific CSF investigations , 2009, European journal of neurology.

[28]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[29]  D. Řípová,et al.  Structure and Pathology of Tau Protein in Alzheimer Disease , 2012, International journal of Alzheimer's disease.

[30]  H. Pant,et al.  Direct evidence of phosphorylated neuronal intermediate filament proteins in neurofibrillary tangles (NFTs): phosphoproteomics of Alzheimer's NFTs , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  W. M. van der Flier,et al.  Tau and p-tau as CSF biomarkers in dementia: a meta-analysis , 2011, Clinical chemistry and laboratory medicine.

[32]  Y. Pijnenburg,et al.  CSF neurofilament proteins in the differential diagnosis of dementia , 2007, Journal of Neurology, Neurosurgery & Psychiatry.

[33]  E. Janousová,et al.  Addenbrookský kognitivní test – orientační normy pro českou populaci Addenbrooke ’ s Cognitive Examination – Approximate Normal Values for the Czech Population , 2019 .

[34]  K. Blennow,et al.  CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival , 2014, Neurology.

[35]  P. Scheltens,et al.  Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe , 2010, European journal of neurology.

[36]  A. Bartoš,et al.  The Mini-Mental State Examination: Czech Norms and Cutoffs for Mild Dementia and Mild Cognitive Impairment due to Alzheimer's Disease , 2016, Dementia and Geriatric Cognitive Disorders.

[37]  L. Hagberg,et al.  Difference in pathogenesis between herpes simplex virus type 1 encephalitis and tick-borne encephalitis demonstrated by means of cerebrospinal fluid markers of glial and neuronal destruction , 2000, Journal of Neurology.

[38]  Ludwig Kappos,et al.  Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases , 2013, PloS one.

[39]  R. Perrot,et al.  Neuronal intermediate filaments and neurodegenerative disorders , 2009, Brain Research Bulletin.

[40]  A. Bartoš,et al.  Serum and cerebrospinal fluid light neurofilaments and antibodies against them in clinically isolated syndrome and multiple sclerosis , 2013, Journal of Neuroimmunology.

[41]  Henrik Zetterberg,et al.  Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression. , 2016, JAMA neurology.

[42]  M. Costa,et al.  The neurofilament triplet is present in distinct subpopulations of neurons in the central nervous system of the guinea-pig , 1992, Neuroscience.

[43]  P. Scheltens,et al.  CSF Neurofilaments in Frontotemporal Dementia Compared with Early Onset Alzheimer’s Disease and Controls , 2007, Dementia and Geriatric Cognitive Disorders.

[44]  Hang Su,et al.  Plasma neurofilament light chain levels in Alzheimer’s disease , 2017, Neuroscience Letters.

[45]  William T. Hu,et al.  Phosphorylated tau as a candidate biomarker for amyotrophic lateral sclerosis. , 2014, JAMA neurology.